We are live on !
Find out more
Great Point Partners Portfolio holdings
AUM
$529M
Turnover
44.44%
1-Year Est. Return
337.4%
This Fund
S&P 500
This Quarter Est. Return
+27.32%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.23%
AUM
$529M
AUM Growth
+$94M
(+22%)
Cap. Flow
-$41.6M
Cap. Flow % of AUM
Cap. Flow %
-7.87%
Top 10 Holdings %
Top 10 Hldgs %
51.64%
Holding
54
New
12
Increased
7
Reduced
10
Closed
12
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.4
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abivax
ABVX
|
+$23.1M |
| 2 |
Vera Therapeutics
VERA
|
+$15M |
| 3 |
Sagimet Biosciences
SGMT
|
+$13.8M |
| 4 |
Definium Therapeutics
DFTX
|
+$10.5M |
| 5 |
Immix Biopharma
IMMX
|
+$8.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apogee Therapeutics
APGE
|
+$31.5M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
+$16.2M |
| 3 |
KalVista Pharmaceuticals
KALV
|
+$13.6M |
| 4 |
Immunovant
IMVT
|
+$13.6M |
| 5 |
Jade Biosciences
JBIO
|
+$13.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.18% |
| 2 | Miscellaneous | 19.78% |
| 3 | Financials | 2.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Pharvaris
PHVS
$2.36B
| – | – |
-82,800
| Closed | -$2.34M | – |
|
52
Tenax Therapeutics
TENX
$73.8M
| – | – |
-327,307
| Closed | -$5.23M | – |
|
53
Unicycive Therapeutics
UNCY
$98.9M
| – | – |
-796,558
| Closed | -$5.24M | – |
|
54
Zenas BioPharma
ZBIO
$1.9B
| – | – |
-524,066
| Closed | -$10.2M | – |
|
Similar funds
GECH
H2CM
Great Point Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Great Point Partners held 54 positions worth $529M, up 22% from $435M the previous quarter. Its ten largest holdings account for 52% of the portfolio.
Great Point Partners withdrew a net $41.6M in Q2 2026, closing 12 positions and reducing 10 holdings. Its most notable exit was Apogee Therapeutics, an estimated $31.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Great Point Partners opened a new position in Abivax worth $27.2M.
- Great Point Partners's largest Q2 2026 buy was Abivax: 204,314 shares worth $27.2M.
- Great Point Partners added most to Vera Therapeutics in Q2 2026, an estimated $15M increase.
- Great Point Partners's biggest Q2 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $16.2M.
- Great Point Partners fully exited Apogee Therapeutics in Q2 2026, selling an estimated $31.5M.
- Great Point Partners's ten largest holdings make up 52% of its $529M portfolio in Q2 2026.
- Great Point Partners opened 12 new positions and closed 12 in Q2 2026.
- Great Point Partners's portfolio value rose 22% quarter-over-quarter to $529M.
Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.